Jazz Pharmaceuticals
JAZZ
318 hedge funds and large institutions have $7.03B invested in Jazz Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 73 funds opening new positions, 85 increasing their positions, 134 reducing their positions, and 33 closing their positions.
121% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 33
14% more capital invested
Capital invested by funds: $6.17B → $7.03B (+$868M)
14% more funds holding
Funds holding: 280 → 318 (+38)
19% less funds holding in top 10
Funds holding in top 10: 16 → 13 (-3)
24% less call options, than puts
Call options by funds: $106M | Put options by funds: $140M
37% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 134
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$353M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$252M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$191M |
| 4 |
Jennison Associates
New York
|
+$147M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$112M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
-$403M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$83.3M |
| 3 |
Bank of New York Mellon
New York
|
-$52.7M |
| 4 |
HCM
Hoplite Capital Management
New York
|
-$49.9M |
| 5 |
CCM
Century Capital Management
Boston,
Massachusetts
|
-$48.6M |
JAZZ Hedge Fund Activity: Q1 2014 in Review
318 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2014, worth a combined $7.03B — up 14% from $6.17B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new JAZZ positions and 33 closed out — a net gain of 40 holders — while 85 added to existing stakes and 134 trimmed.
The largest buyer was Lone Pine Capital, opening a new position worth an estimated $353M. The largest seller was Kohlberg Kravis Roberts & Co, exiting entirely with an estimated $403M sold.
- 318 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2014, up from 280 in Q4 2013.
- Funds reported $7.03B of Jazz Pharmaceuticals stock for Q1 2014, up 14% quarter-over-quarter.
- 73 funds opened new Jazz Pharmaceuticals positions in Q1 2014 and 33 closed out, a net change of +40 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2014 was Lone Pine Capital, an estimated $353M added.
- The largest Jazz Pharmaceuticals seller in Q1 2014 was Kohlberg Kravis Roberts & Co, an estimated $403M sold.
Based on aggregated 13F filings for Q1 2014.